Christopher Lock, MD
Clinical Neurophysiology · Stanford, CANPI 1427205061
Payments from drug & device makers
Across 271 payments — averaging $4869.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$439K
- Genentech, Inc.$388K
- Sanofi$149K
- AbbVie$127K
- Biogen$57K
- Novartis$40K
- plus $121K from 10 others
Across 16 payments — averaging $174.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$42,67427%
- Speaking & faculty fees$90,20057%
- Travel & lodging$21,86814%
- Food & beverage$4,2033%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 3 | $439,244 |
| Genentech, Inc. | 42 | $388,113 |
| Sanofi | 47 | $148,584 |
| AbbVie | 27 | $126,525 |
| Biogen | 47 | $56,548 |
| Novartis | 10 | $40,011 |
| Mallinckrodt Enterprises LLC | 4 | $26,708 |
| Amgen(2 entities) | 29 | $25,259 |
| Mallinckrodt Hospital Products Inc. | 6 | $18,885 |
| Bristol Myers Squibb | 23 | $16,255 |
| Roche Products Limited | 4 | $9,632 |
| EMD Serono, Inc. | 10 | $8,545 |
| E.r. Squibb & Sons, L.L.C. | 5 | $6,000 |
| AstraZeneca | 12 | $5,487 |
| Greenwich Biosciences, Inc. | 1 | $3,808 |
| Sanofi-aventis U.S. LLC | 1 | $91 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,319,694 in reported general payments places this provider in the 95th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 35 | $372,034 |
| Dalfampridine ErDalfampridine | 29 | $4,980 |
| Baclofen | 54 | $2,677 |
| Oxcarbazepine | 16 | $1,415 |
| Gabapentin | 70 | $1,271 |
| Pregabalin | 25 | $1,169 |
| Levetiracetam | 18 | $710 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 14 | $237 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Stanford
- Mitchell MiglisStanford$826K
- Srikanth MuppidiStanford$761K
- Helen Bronte-StewartStanford$672K
- Laurice YangStanford$477K
- Kathleen PostonStanford$458K
- Safwan JaradehStanford$194K
- Margaret FerrisStanford$18K
- Jaime LopezStanford$1K
- Sungho ChoStanford$1K
- Felix ChangStanford$974
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.